Hengy C, Eberlé F, Gazin P, Kouka-Bemba D, Gelas H, Jambou R
OCEAC.
Bull Soc Pathol Exot. 1990;83(1):61-5.
This study appreciated the efficiency of uncomplicated malaria second line treatment (P. falciparum) in an area with high level of chemoresistance. No therapeutic failure was found with sulfadoxine-pyrimethamine (Fansidar), and mefloquine-sulfadoxine-pyrimethamine (Fansimef), in contrast with a rate of 8% with quinine. The authors discuss the place of these therapeutic, in the treatment of malaria.
本研究评估了在耐药性较高地区单纯性疟疾二线治疗（恶性疟）的疗效。与奎宁8%的治疗失败率相比，磺胺多辛-乙胺嘧啶（Fansidar）和甲氟喹-磺胺多辛-乙胺嘧啶（Fansimef）未发现治疗失败情况。作者讨论了这些治疗方法在疟疾治疗中的地位。
